Compare iShares 10 20 Year Treasury Bond ETF (TLH) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 10 20 Year Treasury Bond ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $94.01 (market cap $11.47B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: iShares 10 20 Year Treasury Bond ETF is far larger — about 2.4× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares 10 20 Year Treasury Bond ETF for 62 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| TLH | TVTX | |
|---|---|---|
Market Cap | $11.47B | $4.88B |
Volume | 2,063,925 | 1,668,577 |
Sector | Fixed Income | Health |
52-Week High | $105.36 | $67.52 |
52-Week Low | $91.34 | $26.79 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLH, the iShares 10-20 Year Treasury Bond ETF, trades at $92.56 with a slight 0.34% daily gain amid a challenging bond market environment. Technical indicators signal a bearish trend with selling pressure outweighing buying signals. Recent trading volume spikes indicate heightened investor interest as Treasury yields reach multi-decade highs, creating volatility for long-duration bond ETFs.
The outlook remains cautious as rising interest rates pressure bond prices, though the ETF provides exposure to US Treasury securities. Key risks include continued Fed tightening and inflation concerns, while potential stabilization in yields could offer support. Institutional activity shows mixed positioning with some funds reducing exposure.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
